Zobrazeno 61 - 70
of 225
pro vyhledávání: '"Hisato Kawakami"'
Autor:
Yuichiro, Doki, Jaffer A, Ajani, Ken, Kato, Jianming, Xu, Lucjan, Wyrwicz, Satoru, Motoyama, Takashi, Ogata, Hisato, Kawakami, Chih-Hung, Hsu, Antoine, Adenis, Farid, El Hajbi, Maria, Di Bartolomeo, Maria I, Braghiroli, Eva, Holtved, Sandra A, Ostoich, Hye R, Kim, Masaki, Ueno, Wasat, Mansoor, Wen-Chi, Yang, Tianshu, Liu, John, Bridgewater, Tomoki, Makino, Ioannis, Xynos, Xuan, Liu, Ming, Lei, Kaoru, Kondo, Apurva, Patel, Joseph, Gricar, Ian, Chau, Yuko, Kitagawa, Rachna T, Shroff
Publikováno v:
Doki, Y, Ajani, J A, Kato, K, Xu, J, Wyrwicz, L, Motoyama, S, Ogata, T, Kawakami, H, Hsu, C H, Adenis, A, El Hajbi, F, Di Bartolomeo, M, Braghiroli, M I, Holtved, E, Ostoich, S A, Kim, H R, Ueno, M, Mansoor, W, Yang, W C, Liu, T, Bridgewater, J, Makino, T, Xynos, I, Liu, X, Lei, M, Kondo, K, Patel, A, Gricar, J, Chau, I, Kitagawa, Y & CheckMate 648 Trial Investigators 2022, ' Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma ', The New England Journal of Medicine, vol. 386, no. 5, pp. 449-462 . https://doi.org/10.1056/NEJMoa2111380
BACKGROUND: First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esoph
Autor:
Shinichiro, Suzuki, Kimio, Yonesaka, Takeshi, Teramura, Toshiyuki, Takehara, Ryoji, Kato, Hitomi, Sakai, Koji, Haratani, Junko, Tanizaki, Hisato, Kawakami, Hidetoshi, Hayashi, Kazuko, Sakai, Kazuto, Nishio, Kazuhiko, Nakagawa
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(2)
Autor:
Kazuhiro Nishikawa, Kazumasa Fujitani, Yutaka Kimura, Atsushi Takeno, Yoichi Makari, Jin Matsuyama, Ryohei Kawabata, Taroh Satoh, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa, Tetsuji Terazawa, Yukinori Kurokawa
Publikováno v:
Gastric Cancer. 24:428-434
Cisplatin plus S-1 (CS) is the standard first-line chemotherapy for advanced gastric cancer (AGC) in Japan. A previous phase III trial showed that docetaxel plus S-1 (DS) was effective for AGC without measurable lesions, but no studies have compared
Autor:
Kohei Shitara, Hisato Kawakami, Jeeyun Lee, DESTINY-Gastric Investigators, Hyun-Cheol Chung, Akihito Kojima, Daisuke Sakai, Min-Hee Ryu, Masahiro Sugihara, Kensei Yamaguchi, Hiroshi Yabusaki, Satoru Iwasa, Takahiro Kamio, Naotoshi Sugimoto, Yung-Jue Bang, Yoshinori Kawaguchi, Kaku Saito
Publikováno v:
New England Journal of Medicine. 382:2419-2430
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficac
Autor:
Yutaka Kimura, Hisato Kawakami, Masahiro Goto, Youichi Makari, Takao Tamura, Naotoshi Sugimoto, Jin Matsuyama, Yukinori Kurokawa, Toshimasa Tsujinaka, Daisuke Sakai, Shunji Endo, Kazumasa Fujitani, Yusuke Akamaru, Toshio Shimokawa, Shigeyuki Tamura, Taroh Satoh
Publikováno v:
International Journal of Clinical Oncology. 25:1635-1643
We previously reported the HERBIS-4A phase II trial comparing S-1 plus cisplatin (SP) with capecitabine plus cisplatin (XP) in chemotherapy-naive patients with HER2-negative advanced gastric cancer (GC). We performed a pooled analysis of HERBIS-4A an
Autor:
Hisato Kawakami, Naotoshi Sugimoto, Takeshi Kato, Taroh Satoh, Masaki Tsujie, Shu Okamura, Yukihiko Tokunaga, Shigeyoshi Iwamoto, Takashi Ohta, Masato Nakamura, Masahito Kotaka, Taishi Hata, Toshio Shimokawa, Hideyuki Mishima, Yukinori Kurokawa, Yasuhiro Miyake, Toshio Otsuji, Masahiro Goto
Publikováno v:
International Journal of Clinical Oncology. 25:1291-1298
Older or frail patients are often underrepresented in clinical trials for metastatic colorectal cancer (mCRC). We here assessed the efficacy and safety of 5-fluorouracil (5-FU)–leucovorin plus bevacizumab in such patients. The study (OGSG 0802) was
Autor:
Shunji Endo, Tetsuji Terazawa, Masahiro Goto, Ryo Tanaka, Takeshi Kato, Kazumasa Fujitani, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh
Publikováno v:
BMC cancer. 22(1)
Background Large type 3 and type 4 gastric cancers have extremely poor prognoses. To address this, neoadjuvant chemotherapy may be a promising approach. The phase III JCOG0501 study, conducted to confirm the superiority of neoadjuvant S-1 plus cispla
Autor:
Hiroyuki, Kodama, Motoki, Yoshida, Masahiro, Goto, Masato, Nakamura, Hiroko, Hasegawa, Atsushi, IKeda, Yukihiko, Tokunaga, Kazufumi, Tanigawa, Tetsuji, Terazawa, Daisuke, Sakai, Yukinori, Kurokawa, Hisato, Kawakami, Toshio, Shimokawa, Taroh, Satoh
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 48(10)
Regorafenib(Rego)is the salvage line standard treatment for metastatic colorectal cancer(mCRC), which often causes severe toxicities, such as hand-foot syndrome. Previously, we reported that in phase Ⅱ study, S-1 plus bevacizumab( Bev)(SB)showed fa
Autor:
Jin Matsuyama, Tetsuji Terazawa, Masahiro Goto, Ryohei Kawabata, Shunji Endo, Motohiro Imano, Shoichiro Fujita, Yusuke Akamaru, Hirokazu Taniguchi, Mitsutoshi Tatsumi, Sang-Woong Lee, Hisato Kawakami, Yukinori Kurokawa, Toshio Shimokawa, Daisuke Sakai, Takeshi Kato, Kazumasa Fujitani, Taroh Satoh
Publikováno v:
The oncologist. 27(4)
Background We previously reported the good feasibility and favorable efficacy of perioperative capecitabine plus oxaliplatin (CapeOx) in patients (pts) with clinical T3(SS)/T4a(SE) N1-3 M0 gastric cancer (GC) in a phase II study in which the patholog
Autor:
Hisato, Kawakami, Sota, Ogata
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 48(6)
Precision medicine, which considers the genetics of the tumor tissues and cells for selection of the most appropriate treatment strategy, has recently been developed for colorectal cancer. The BRAF mutation status in colorectal cancer has been tested